Recent advancements in immunotherapy provide new treatment avenues for advanced esophageal cancer, particularly for squamous cell carcinoma and esophagogastric adenocarcinoma. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, are now approved in various treatment settings, including adjuvant therapy for patients post-surgery and first-line treatments combined with chemotherapy. These developments improve accessibility to effective therapies, regardless of PD-L1 status, marking a significant progress in personalized medicine for esophageal cancer treatment.
Review by Huber Y, Moehler M and Högner A in Innov Surg Sci
© 2024 the author(s), published by De Gruyter, Berlin/Boston.